Effimune and In Cell Art collaborate to develop a novel therapeutic approach in immunology

PR 110216Final The two biotechnology companies in Nantes develop a novel approach aiming at the production of therapeutic antibodies directly by the patient.

Effimune and In Cell Art announce their collaboration to launch the “Efficace” project. This project aims to develop an innovative cancer immunotherapy strategy combining a novel therapeutic target and a transfer approach based on the synthetic intracellular delivery of mRNA (messenger Ribonucleic Acid) encoding validated monoclonal antibodies. This new approach consists of producing therapeutic antibodies from the patient’s body rather than those produced in bioreactors (classical approach).

Read the full press release